Beijing SL Pharmaceutical Hits Day Low of CNY 5.90 Amid Price Pressure

Beijing SL Pharmaceutical Co., Ltd. experienced a significant decline today, with the stock dropping by 10.06% and reaching an intraday low of CNY 5.90. This midcap company operates within the Pharmaceuticals & Biotechnology sector and has faced consistent challenges reflected in its performance metrics. Over the past year, Beijing SL has reported a staggering decline of 24.46%, significantly underperforming the China Shanghai Composite, which has gained 7.03% during the same period. The company's long-term growth prospects appear weak, with net sales decreasing at an annual rate of 12.67% and operating profit plummeting by 231.38% over the last five years. Financial indicators reveal a low Return on Capital Employed (ROCE) of 3.40%, highlighting inefficiencies in management and profitability. The company’s recent financial results also show a net profit of CNY -659.6 million, marking a dramatic decline of 4,490.24%. Additionally, the inventory turnover ratio stands at a low 0.42 times, further emphasizing operational difficulties. Overall, Beijing SL Pharmaceutical Co., Ltd. continues to face significant hurdles, as evidenced by its performance metrics and market position.